Svein Arild Mathisen
Director/Board Member at SPRINT BIOSCIENCE AB
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Thomas Edlund | M | - |
Balticgruppen Bio AB
 Balticgruppen Bio AB Pharmaceuticals: MajorHealth Technology Balticgruppen Bio AB is a Swedish biopharmaceutical company that develops activated protein kinase. The company was founded by Olof Karlsson, Thomas Edlund, and Helena Edlund. Thomas Edlund has been the CEO since incorporation.
Betagenon Sweden AB
 Betagenon Sweden AB Pharmaceuticals: MajorHealth Technology Betagenon AB engages in development of AMP-activated protein kinase (AMPK) activator compounds chronic energy balance disorders diseases. The company was founded by Helena Edlund, Thomas Edlund and Olof Karlsson and is headquartered in Umea, Sweden. | - |
| Björn Frendéus | M | 51 | 23 years | |
| Helena Edlund | M | - |
Balticgruppen Bio AB
Balticgruppen Bio AB Pharmaceuticals: MajorHealth Technology Balticgruppen Bio AB is a Swedish biopharmaceutical company that develops activated protein kinase. The company was founded by Olof Karlsson, Thomas Edlund, and Helena Edlund. Thomas Edlund has been the CEO since incorporation.
Betagenon Sweden AB
Betagenon Sweden AB Pharmaceuticals: MajorHealth Technology Betagenon AB engages in development of AMP-activated protein kinase (AMPK) activator compounds chronic energy balance disorders diseases. The company was founded by Helena Edlund, Thomas Edlund and Olof Karlsson and is headquartered in Umea, Sweden. | - |
| Andreas Nordberg | M | - |
Balticgruppen Bio AB
Balticgruppen Bio AB Pharmaceuticals: MajorHealth Technology Balticgruppen Bio AB is a Swedish biopharmaceutical company that develops activated protein kinase. The company was founded by Olof Karlsson, Thomas Edlund, and Helena Edlund. Thomas Edlund has been the CEO since incorporation.
Betagenon Sweden AB
Betagenon Sweden AB Pharmaceuticals: MajorHealth Technology Betagenon AB engages in development of AMP-activated protein kinase (AMPK) activator compounds chronic energy balance disorders diseases. The company was founded by Helena Edlund, Thomas Edlund and Olof Karlsson and is headquartered in Umea, Sweden. | - |
| Anders Bergman | M | 60 |
Athera Biotechnologies AB
 Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | - |
| Gunnar Olof Olsson | M | 71 |
Betagenon Bio AB
Betagenon Sweden AB
Betagenon Sweden AB Pharmaceuticals: MajorHealth Technology Betagenon AB engages in development of AMP-activated protein kinase (AMPK) activator compounds chronic energy balance disorders diseases. The company was founded by Helena Edlund, Thomas Edlund and Olof Karlsson and is headquartered in Umea, Sweden.
Athera Biotechnologies AB
Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | 3 years |
| Martin Andersson | M | 53 | 15 years | |
| Nils Rune Nordlander | M | 68 | 14 years | |
| Olof Karlsson | M | - |
Balticgruppen Bio AB
Balticgruppen Bio AB Pharmaceuticals: MajorHealth Technology Balticgruppen Bio AB is a Swedish biopharmaceutical company that develops activated protein kinase. The company was founded by Olof Karlsson, Thomas Edlund, and Helena Edlund. Thomas Edlund has been the CEO since incorporation. | - |
| James Hall | M | - |
Athera Biotechnologies AB
Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | - |
| Olof Andries Blokzijl | M | 54 |
Genagon Therapeutics AB
 Genagon Therapeutics AB BiotechnologyHealth Technology Genagon Therapeutics AB engages in the provision of scientific and technical research and development services. It develops and commercializes pharmaceuticals and medical products. The company was founded by Johan Erik Simon Fredriksson and Olof Andries Blokzijl on June 5, 2015 and is headquartered in Stockholm, Sweden. | 9 years |
| Folke Per-Olof Wallström | M | 75 | 14 years | |
| Kerstin Valinder-Strinnholm | F | 64 | 9 years | |
| Stefan Ericsson | M | 61 | 26 years | |
| Fredrik Lehmann | M | 48 | 5 years | |
| Knut Pettersson | M | - |
Athera Biotechnologies AB
Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | - |
| Mathias Skalmstad | M | 51 | 13 years | |
| Behshad Sheldon | F | 61 | 6 years | |
| Olle Korsgren | M | - |
iCell Science AB
| - |
| Anna Carina Schmidt | F | 66 |
Athera Biotechnologies AB
Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | - |
| Johan Erik Simon Fredriksson | M | 51 |
Genagon Therapeutics AB
Genagon Therapeutics AB BiotechnologyHealth Technology Genagon Therapeutics AB engages in the provision of scientific and technical research and development services. It develops and commercializes pharmaceuticals and medical products. The company was founded by Johan Erik Simon Fredriksson and Olof Andries Blokzijl on June 5, 2015 and is headquartered in Stockholm, Sweden. | 9 years |
| Agneta Svedberg | F | 61 | 9 years | |
| Jan Lundberg | M | 70 |
Balticgruppen Bio AB
Balticgruppen Bio AB Pharmaceuticals: MajorHealth Technology Balticgruppen Bio AB is a Swedish biopharmaceutical company that develops activated protein kinase. The company was founded by Olof Karlsson, Thomas Edlund, and Helena Edlund. Thomas Edlund has been the CEO since incorporation.
Betagenon Sweden AB
Betagenon Sweden AB Pharmaceuticals: MajorHealth Technology Betagenon AB engages in development of AMP-activated protein kinase (AMPK) activator compounds chronic energy balance disorders diseases. The company was founded by Helena Edlund, Thomas Edlund and Olof Karlsson and is headquartered in Umea, Sweden. | 5 years |
| Karin From | F | 54 | 1 years | |
| Martin Gunhaga | M | - |
Betagenon Sweden AB
Betagenon Sweden AB Pharmaceuticals: MajorHealth Technology Betagenon AB engages in development of AMP-activated protein kinase (AMPK) activator compounds chronic energy balance disorders diseases. The company was founded by Helena Edlund, Thomas Edlund and Olof Karlsson and is headquartered in Umea, Sweden.
Balticgruppen Bio AB
Balticgruppen Bio AB Pharmaceuticals: MajorHealth Technology Balticgruppen Bio AB is a Swedish biopharmaceutical company that develops activated protein kinase. The company was founded by Olof Karlsson, Thomas Edlund, and Helena Edlund. Thomas Edlund has been the CEO since incorporation. | - |
| James Hall | M | - |
Betagenon Sweden AB
Betagenon Sweden AB Pharmaceuticals: MajorHealth Technology Betagenon AB engages in development of AMP-activated protein kinase (AMPK) activator compounds chronic energy balance disorders diseases. The company was founded by Helena Edlund, Thomas Edlund and Olof Karlsson and is headquartered in Umea, Sweden. | 3 years |
| Li Ming Gan | M | - |
Balticgruppen Bio AB
Balticgruppen Bio AB Pharmaceuticals: MajorHealth Technology Balticgruppen Bio AB is a Swedish biopharmaceutical company that develops activated protein kinase. The company was founded by Olof Karlsson, Thomas Edlund, and Helena Edlund. Thomas Edlund has been the CEO since incorporation. | - |
| Li Ming Gan | M | - |
Betagenon Sweden AB
Betagenon Sweden AB Pharmaceuticals: MajorHealth Technology Betagenon AB engages in development of AMP-activated protein kinase (AMPK) activator compounds chronic energy balance disorders diseases. The company was founded by Helena Edlund, Thomas Edlund and Olof Karlsson and is headquartered in Umea, Sweden. | - |
| Markus Skog Olsson | M | - |
Balticgruppen Bio AB
Balticgruppen Bio AB Pharmaceuticals: MajorHealth Technology Balticgruppen Bio AB is a Swedish biopharmaceutical company that develops activated protein kinase. The company was founded by Olof Karlsson, Thomas Edlund, and Helena Edlund. Thomas Edlund has been the CEO since incorporation. | - |
| Anne-Marie Wenthzel | F | - | 13 years | |
| Johan Lund | M | 67 |
Genagon Therapeutics AB
Genagon Therapeutics AB BiotechnologyHealth Technology Genagon Therapeutics AB engages in the provision of scientific and technical research and development services. It develops and commercializes pharmaceuticals and medical products. The company was founded by Johan Erik Simon Fredriksson and Olof Andries Blokzijl on June 5, 2015 and is headquartered in Stockholm, Sweden. | 5 years |
| Karin von Wachenfeldt | M | - |
Genagon Therapeutics AB
Genagon Therapeutics AB BiotechnologyHealth Technology Genagon Therapeutics AB engages in the provision of scientific and technical research and development services. It develops and commercializes pharmaceuticals and medical products. The company was founded by Johan Erik Simon Fredriksson and Olof Andries Blokzijl on June 5, 2015 and is headquartered in Stockholm, Sweden. | - |
| Richard Åhlberg | M | - |
Genagon Therapeutics AB
Genagon Therapeutics AB BiotechnologyHealth Technology Genagon Therapeutics AB engages in the provision of scientific and technical research and development services. It develops and commercializes pharmaceuticals and medical products. The company was founded by Johan Erik Simon Fredriksson and Olof Andries Blokzijl on June 5, 2015 and is headquartered in Stockholm, Sweden. | - |
| Moa Fransson | M | - |
Genagon Therapeutics AB
Genagon Therapeutics AB BiotechnologyHealth Technology Genagon Therapeutics AB engages in the provision of scientific and technical research and development services. It develops and commercializes pharmaceuticals and medical products. The company was founded by Johan Erik Simon Fredriksson and Olof Andries Blokzijl on June 5, 2015 and is headquartered in Stockholm, Sweden. | - |
| Annette Mattsson | F | 58 | 7 years | |
| Richard Jameson | M | 60 | 8 years | |
| Torsten Malmström | M | 56 | 11 years | |
| Michael Owens | M | 68 |
Athera Biotechnologies AB
Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | - |
| Anders Birger Nordström | M | 71 |
Genagon Therapeutics AB
Genagon Therapeutics AB BiotechnologyHealth Technology Genagon Therapeutics AB engages in the provision of scientific and technical research and development services. It develops and commercializes pharmaceuticals and medical products. The company was founded by Johan Erik Simon Fredriksson and Olof Andries Blokzijl on June 5, 2015 and is headquartered in Stockholm, Sweden. | - |
| Carl Johan Kördel | M | 62 |
Athera Biotechnologies AB
Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | - |
| Sten Gunnar Otto Skolling | M | 62 |
Athera Biotechnologies AB
Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | - |
| Björn Magnus Sjöstrand | M | 56 | 3 years | |
| Johan Emilsson | M | 40 | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Karl Arne Krister Borrebaeck | M | 76 | - | |
| Björn Eskil Olsson | M | 79 | 6 years | |
| Edith Olga Elisabeth Lindner | F | 68 | - | |
| Marianne Dicander Alexandersson | F | 65 | 5 years | |
| Markus Johnsson | M | 52 | 14 years | |
| Ulrika T. Mattson | F | 56 | 10 years | |
| Erik Kinnman | M | 66 | 2 years | |
| Lars Ingelmark | M | 75 | 12 years | |
| Lars Rickard Backsell | M | 72 | - | |
| Sten Westerberg | M | 64 | - | |
| Vessela Alexieva | F | 65 | - | |
| Steven Glazer | M | 76 | - | |
| Kenth Ingemar Petersson | M | 68 | - | |
| Björn O. Nilsson | M | 68 | - | |
| Ulla Cristina Glad | M | 72 | 11 years | |
| Martin Fredrik Jonsson | M | 63 | - | |
| Eva Pinotti Lindqvist | F | 61 | 8 years | |
| Anna Cherouvrier Hansson | F | 51 | - | |
| Cecilia Callmer | F | 50 | - | |
| Urban Paulsson | M | 60 | 4 years | |
| Sidonie Karlsson | F | 49 | - | |
| Magnus Korsgren | M | 55 | - | |
| Stephan Björk | M | 49 | - | |
| Rein Piir | M | 66 | - | |
| Karl-Olof Borg | M | 83 | - | |
| Martin Wiles | M | 61 | - | |
| Karin Almqvist Liwendahl | F | 62 | 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Sweden | 70 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Svein Arild Mathisen
- Personal Network
